SL
ALNY icon

Salomon & Ludwin’s Alnylam Pharmaceuticals ALNY Stock Holding History

Salomon & Ludwin’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5K Buy
111
+33
+42% +$9.95K ﹤0.01% 779
2026
Q1 		$24.9K Buy
78
+55
+239% +$18.7K ﹤0.01% 930
2025
Q4 		$9.15K Sell
23
-37
-62% -$16.4K ﹤0.01% 1493
2025
Q3 		$27.4K Buy
+60
New +$24.4K ﹤0.01% 632
2019
Q3 		– Sell
-150
Closed -$11K – 208
2019
Q2 		$11K Buy
+150
New +$11.5K ﹤0.01% 152

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's ALNY Position: Q2 2026 in Review

Salomon & Ludwin increased its Alnylam Pharmaceuticals (ALNY) stake by 42% in Q2 2026, buying an estimated $9.95K and bringing the position to 111 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Salomon & Ludwin first reported a position in ALNY in Q2 2019 and has held it in 5 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Salomon & Ludwin held 111 shares of Alnylam Pharmaceuticals worth $33.5K as of Q2 2026.
  • Salomon & Ludwin bought 33 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.95K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #779 holding.
  • Salomon & Ludwin first reported a position in Alnylam Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.